Tavneos (Avacopan) Patent Expiration, LOE Window & CMS Spending
Tavneos (Avacopan) by Amgen: FDA Orange Book core substance LOE 2039-11-27, 0 AB generics, $101.6M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Amgen |
| FDA Application & Pathway | N214487 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2039-11-27 |
| Last Listed Patent or Exclusivity Date | 2039-11-27 |
| Orange Book Patents (*PED Extensions) | 4 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $101.6M |
| 2024 Medicare Part D Spend | $76.0M |
| 2024 Medicaid Spend | $25.5M |
| Reported Wholesale Price Change (CA SB 17) | 4 WAC filings (max 23.8% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Amgen across sibling Meru public-data platforms.